查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1612128

亞伯氏症候群市場：按產品類型、基因類型和最終用戶分類 - 全球預測 2025-2030

Alport Syndrome Market by Product (Diagnosis, Treatments), Genetic Type (Autosomal Dominant Alport Syndrome, Autosomal Recessive Alport Syndrome, X-linked Alport Syndrome), End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

亞伯氏症候群市場2023年估值為15.9億美元，預計到2024年將達到17.7億美元，複合年成長率為11.54%，到2030年將達到34.3億美元。

亞伯氏症候群是一種罕見的遺傳性疾病，其特徵是進行性性腎臟疾病、聽力損失和眼睛異常，嚴重影響生活品質。該市場對研究和應用的需求源於對早期診斷和有效治療方案以管理症狀和改善患者預後的迫切需求。最終用途範圍主要包括醫療保健提供者、患者、研究機構和製藥公司。市場開拓洞察表明，由於基因檢測的進步、意識的提高和研發活動的活性化，成長潛力巨大。主要影響因素包括醫療保健支出增加、基因治療技術創新以及政府對罕見疾病的支持措施。最新的商機之一在於開發基因療法和個人化醫療方法等新型療法，這有望在患者管理方面取得重大進展。公司可以透過投資與研究機構的合作夥伴關係並利用人工智慧進行早期診斷和治療客製化來受益。然而，由於治療費用飆升、公眾缺乏認知以及因症狀與其他疾病重疊而誤診，市場面臨限制。嚴格的法律規範和有限的患者群體帶來了額外的挑戰。儘管存在這些障礙，創新最好的方向是改進診斷技術和開發侵入性較小且具成本效益的治療方法。鼓勵生物技術公司和學術研究中心之間的夥伴關係可以刺激創新。您還可以透過參與患者宣傳和教育活動來發展您的業務，以提高意識並提高診斷率。總體而言，亞伯氏症候群市場是一個充滿希望但充滿挑戰的市場，需要研究和開發、患者參與和跨部門合作策略來克服當前的限制並做出有意義的臨床進展投資。這個市場的性質需要在治療解決方案的創新與現有挑戰的策略管理之間取得平衡，以充分發揮其潛力。

主要市場統計
基準年[2023] 15.9億美元
預測年份 [2024] 17.7億美元
預測年份 [2030] 34.3億美元
複合年成長率（%） 11.54%

市場動態：揭示快速發展的亞伯氏症候群市場的關鍵市場洞察

供需的動態交互作用正在改變亞伯氏症候群市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 全球遺傳病患疾病率不斷上升
    • 亞伯氏症候群基因診斷解決方案持續取得進展
    • 臨床測試中新治療方法的出現
  • 市場限制因素
    • 與亞伯氏症候群的手術和治療過程相關的高成本
  • 市場機會
    • 增加研發活動
    • 增加公共和私人對罕見疾病研究的投資
  • 市場問題
    • 基因藥物開發的複雜性

波特五力：駕馭亞伯氏症候群市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解亞伯氏症候群市場的外部影響

外部宏觀環境因素在塑造亞伯氏症候群市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解亞伯氏症候群市場的競爭格局

對亞伯氏症候群市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：亞伯氏症候群市場供應商的績效評估

FPNV 定位矩陣是評估亞伯氏症候群市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製亞伯氏症候群市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對亞伯氏症候群市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地遺傳性疾病的發生率正在增加
      • 亞伯氏症候群基因診斷解決方案持續取得進展
      • 臨床測試中新治療方法和療法的出現
    • 抑制因素
      • 與亞伯氏症候群手術和治療過程相關的高費用
    • 機會
      • 增加研發活動
      • 增加公共和私營部門對罕見疾病研究的投資
    • 任務
      • 與遺傳藥物開發相關的複雜性
  • 市場區隔分析
    • 產品：加速亞伯氏症候群早期診斷解決方案的創新研發
    • 基因型：X連鎖亞伯氏症候群症候群盛行率上升促進治療進展
    • 最終用途：擴大醫院和診所活動以提供廣泛的治療和疾病管理
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章亞伯氏症候群市場：依產品

  • 介紹
  • 診斷
    • 驗血
    • 基因檢測
    • 切片檢查
  • 治療
    • 藥品
    • 外科手術

第 7 章亞伯氏症候群市場：依基因型分類

  • 介紹
  • 常染色體顯性亞伯氏症候群症候群
  • 亞伯氏症候群症候群
  • X連鎖亞伯氏症候群

第 8 章亞伯氏症候群市場：依最終用途

  • 介紹
  • 診斷中心及實驗室
  • 醫院/診所

第9章美洲亞伯氏症候群市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太亞伯氏症候群市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲亞伯氏症候群市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Calliditas Therapeutics 憑藉西他那昔治療亞伯氏症候群獲得 FDA 孤兒藥資格認定
    • Eloxx Pharmaceuticals 計劃在 2 期試驗中患者病情緩解後，將 ELX-02 推進到治療帶有無義突變的亞伯氏症候群的關鍵測試中
  • 戰略分析和建議

公司名單

  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Calliditas Therapeutics AB
  • CENTOGENE NV
  • Chinook Therapeutics Inc.
  • Daiichi Sankyo Company, Limited
  • Eloxx Pharmaceuticals, Inc.
  • Eurofins Scientific SE
  • GlaxoSmithKline PLC
  • Illumina Inc
  • Invitae Corp.
  • Merck & Co., Inc.
  • Mylan NV
  • Natera, Inc.
  • Oxalo Therapeutics
  • Pfizer Inc.
  • Quest Diagnostics Incorporated
  • Reata Pharmaceuticals, Inc. by Biogen Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Travere Therapeutics, Inc.
Product Code: MRR-BB4648AFF3B1

The Alport Syndrome Market was valued at USD 1.59 billion in 2023, expected to reach USD 1.77 billion in 2024, and is projected to grow at a CAGR of 11.54%, to USD 3.43 billion by 2030.

Alport Syndrome is a rare genetic disorder characterized by progressive kidney disease, hearing loss, and eye abnormalities, significantly affecting the quality of life. The necessity of research and application in this market stems from the urgent need for early diagnosis and effective treatment options to manage symptoms and improve patient outcomes. The end-use scope primarily involves healthcare providers, patients, research institutions, and pharmaceutical companies. Market insights suggest strong growth potential driven by advancements in genetic testing, increasing awareness, and a surge in research and development activities. Key influencing factors include the rise in healthcare expenditure, technological innovations in genetic therapies, and supportive government policies for rare diseases. One of the latest opportunities lies in developing novel therapeutics, such as gene therapies and personalized medicine approaches, promising significant advancements in patient management. Companies could benefit by investing in collaborations with research institutions and leveraging artificial intelligence for early diagnosis and treatment customization. However, the market faces limitations due to high treatment costs, lack of awareness among the general public, and misdiagnosis due to overlapping symptoms with other diseases. Stringent regulatory frameworks and limited patient pools pose additional challenges. Despite these hurdles, innovation can be best directed towards improving diagnostic technologies and developing less invasive, more cost-effective treatments. Encouraging partnerships between biotech firms and academic research centers could spur innovation. Business growth could also stem from engaging in patient advocacy and education initiatives to raise awareness and increase diagnosis rates. Overall, the market for Alport Syndrome remains promising yet challenging, requiring strategic investments in R&D, patient engagement, and cross-sector collaborations to overcome current limitations and make meaningful clinical advancements. The market's nature demands a balance between innovation in therapeutic solutions and strategic management of existing challenges to realize its full potential.

KEY MARKET STATISTICS
Base Year [2023] USD 1.59 billion
Estimated Year [2024] USD 1.77 billion
Forecast Year [2030] USD 3.43 billion
CAGR (%) 11.54%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Alport Syndrome Market

The Alport Syndrome Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of genetic disorders across the globe
    • Ongoing advancements in genetic diagnostic solutions for Alport syndrome
    • Emerging new treatments and therapies in clinical trials
  • Market Restraints
    • High costs associated with surgeries and treatment processes for Alport syndrome
  • Market Opportunities
    • Increase in the number of research and development activities
    • Growing investment in rare disease research from public & private sectors
  • Market Challenges
    • Complexities associate of the genetic based drug developments

Porter's Five Forces: A Strategic Tool for Navigating the Alport Syndrome Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Alport Syndrome Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Alport Syndrome Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Alport Syndrome Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Alport Syndrome Market

A detailed market share analysis in the Alport Syndrome Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Alport Syndrome Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Alport Syndrome Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Alport Syndrome Market

A strategic analysis of the Alport Syndrome Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Alport Syndrome Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Boehringer Ingelheim International GmbH, Calliditas Therapeutics AB, CENTOGENE N.V., Chinook Therapeutics Inc., Daiichi Sankyo Company, Limited, Eloxx Pharmaceuticals, Inc., Eurofins Scientific SE, GlaxoSmithKline PLC, Illumina Inc, Invitae Corp., Merck & Co., Inc., Mylan N.V., Natera, Inc., Oxalo Therapeutics, Pfizer Inc., Quest Diagnostics Incorporated, Reata Pharmaceuticals, Inc. by Biogen Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., and Travere Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Alport Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Diagnosis and Treatments. The Diagnosis is further studied across Blood Test, Genetic Test, and Kidney Biopsy. The Treatments is further studied across Medications and Surgery.
  • Based on Genetic Type, market is studied across Autosomal Dominant Alport Syndrome, Autosomal Recessive Alport Syndrome, and X-linked Alport Syndrome.
  • Based on End-Use, market is studied across Diagnostic Centers & Laboratories and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of genetic disorders across the globe
      • 5.1.1.2. Ongoing advancements in genetic diagnostic solutions for Alport syndrome
      • 5.1.1.3. Emerging new treatments and therapies in clinical trials
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with surgeries and treatment processes for Alport syndrome
    • 5.1.3. Opportunities
      • 5.1.3.1. Increase in the number of research and development activities
      • 5.1.3.2. Growing investment in rare disease research from public & private sectors
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities associate of the genetic based drug developments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Rising research and development for innovations in early diagnosis solutions of Alport Syndrome
    • 5.2.2. Genetic Type: Ongoing therapeutic advancements in X-linked Alport Syndrome due to its rising prevalence
    • 5.2.3. End-Use: Expansion in hospitals & clinics activities to provide extensive range treatment and disease management
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Alport Syndrome Market, by Product

  • 6.1. Introduction
  • 6.2. Diagnosis
    • 6.2.1. Blood Test
    • 6.2.2. Genetic Test
    • 6.2.3. Kidney Biopsy
  • 6.3. Treatments
    • 6.3.1. Medications
    • 6.3.2. Surgery

7. Alport Syndrome Market, by Genetic Type

  • 7.1. Introduction
  • 7.2. Autosomal Dominant Alport Syndrome
  • 7.3. Autosomal Recessive Alport Syndrome
  • 7.4. X-linked Alport Syndrome

8. Alport Syndrome Market, by End-Use

  • 8.1. Introduction
  • 8.2. Diagnostic Centers & Laboratories
  • 8.3. Hospitals & Clinics

9. Americas Alport Syndrome Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Alport Syndrome Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Alport Syndrome Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Calliditas Therapeutics granted orphan drug designation by the FDA for the treatment of Alport syndrome with setanaxib
    • 12.3.2. Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Boehringer Ingelheim International GmbH
  • 3. Calliditas Therapeutics AB
  • 4. CENTOGENE N.V.
  • 5. Chinook Therapeutics Inc.
  • 6. Daiichi Sankyo Company, Limited
  • 7. Eloxx Pharmaceuticals, Inc.
  • 8. Eurofins Scientific SE
  • 9. GlaxoSmithKline PLC
  • 10. Illumina Inc
  • 11. Invitae Corp.
  • 12. Merck & Co., Inc.
  • 13. Mylan N.V.
  • 14. Natera, Inc.
  • 15. Oxalo Therapeutics
  • 16. Pfizer Inc.
  • 17. Quest Diagnostics Incorporated
  • 18. Reata Pharmaceuticals, Inc. by Biogen Inc.
  • 19. Sanofi S.A.
  • 20. Teva Pharmaceutical Industries Ltd.
  • 21. Travere Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. ALPORT SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. ALPORT SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALPORT SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALPORT SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALPORT SYNDROME MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ALPORT SYNDROME MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ALPORT SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ALPORT SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALPORT SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALPORT SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALPORT SYNDROME MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALPORT SYNDROME MARKET DYNAMICS
  • TABLE 7. GLOBAL ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALPORT SYNDROME MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALPORT SYNDROME MARKET SIZE, BY GENETIC TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALPORT SYNDROME MARKET SIZE, BY KIDNEY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALPORT SYNDROME MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALPORT SYNDROME MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ALPORT SYNDROME MARKET SIZE, BY AUTOSOMAL DOMINANT ALPORT SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALPORT SYNDROME MARKET SIZE, BY AUTOSOMAL RECESSIVE ALPORT SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ALPORT SYNDROME MARKET SIZE, BY X-LINKED ALPORT SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ALPORT SYNDROME MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ALPORT SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 92. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 97. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 102. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 107. TAIWAN ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 112. THAILAND ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. VIETNAM ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ALPORT SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. DENMARK ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. EGYPT ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 138. FINLAND ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 143. FRANCE ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 148. GERMANY ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 153. ISRAEL ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 158. ITALY ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 163. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 168. NIGERIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 173. NORWAY ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 178. POLAND ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 183. QATAR ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 188. RUSSIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH AFRICA ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 203. SPAIN ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 208. SWEDEN ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 213. SWITZERLAND ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 218. TURKEY ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 223. UNITED ARAB EMIRATES ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED KINGDOM ALPORT SYNDROME MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM ALPORT SYNDROME MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM ALPORT SYNDROME MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ALPORT SYNDROME MARKET SIZE, BY GENETIC TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ALPORT SYNDROME MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 233. ALPORT SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 234. ALPORT SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023